Medical Device News Magazine
HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

First Patient Enrolled in Pivotal Atherectomy Clinical Study

Ra Medical received investigational device exemption (IDE) approval for the atherectomy clinical study from the FDA in January 2020.

FDA Approves to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data

PROMISE Sensor Clinical Study is to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the U.S.

Peregrine Post-Market Study Published in the Journal of the American College of Cardiology: Cardiovascular Interventions

Peregrine Post-Market Study is a European multicenter open-label trial that evaluated additional safety and performance of the Peregrine System Infusion Catheter using a neurolytic agent (dehydrated alcohol) delivered into the space outside of the renal (kidney) arteries in 45 patients with systemic hypertension.

Large Clinical Study to Support Underway Reports Diabeloop

Note: In December 2019, the company completed a record-breaking Series B funding round of 31 million euros intended to support its launch strategy in major international markets (particularly in Europe and the United States).

Published Real-World Experience Demonstrates VasQ External Support Improves Outcomes When Adopted as the Standard of Care

The paper demonstrated that using VasQ as the standard of care for radiocephalic fistulas resulted in a significant improvement in his center’s primary fistula failure and longer-term secondary patency rates with less repeat interventions when compared to historical controls.

Publication of COMPASS Study Validating First Scoring Guidelines for WatchPAT™ Device in Diagnosing Sleep Apnea

The COMPASS Study appears online in the Journal of Clinical Sleep Medicine.

Breakthrough Study Published Measuring the Effect of EOTTS to Reduce Medial Knee Compartment Forces

GraMedica reports, the first of its kind, the study measured the in vivo forces acting within the medial knee compartment, before and after EOTTS.

BD Completes Clinical Trial for BD Libertas Wearable Injector Completed

The award-winning Libertas Wearable Injector is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System

BrainsWay advises the results showed a statistically significant improvement in patient-reported assessments of inattention, together with a significant increase in activity that was observed within the dorsolateral prefrontal cortex, a brain area previously shown to express reduced activity in adults with ADHD.

DynaNail Mini Fusion System for Subtalar Fusion Procedures Shows Positive Early Results

The DynaNail Mini Fusion System has been implanted by over 50 orthopedic surgeons in over 50 hospitals across the United States.
spot_imgspot_img

Recent News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”